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Sterol receptor element binding protein-1c
Peroxisome proliferator activated receptor-α
Insulin resistanceSterol receptor element-binding protein-1c (SREBP-1c) and peroxisome proliferator-activated receptor-α
(PPAR-α) mRNA expression was assessed in liver as signaling mechanisms associated with steatosis in obese
patients. Liver SREBP-1c and PPAR-α mRNA (RT-PCR), fatty acid synthase (FAS) and carnitine
palmitoyltransferase-1a (CPT-1a) mRNA (real-time RT-PCR), and n-3 long-chain polyunsaturated fatty acid
(LCPUFA)(GLC) contents, plasma adiponectin levels (RIA), and insulin resistance (IR) evolution (HOMA)
were evaluated in 11 obese patients who underwent subtotal gastrectomy with gastro-jejunal anastomosis
in Roux-en-Y and 8 non-obese subjects who underwent laparoscopic cholecystectomy (controls). Liver
SREBP-1c and FAS mRNA levels were 33% and 70% higher than control values (Pb0.05), respectively, whereas
those of PPAR-α and CPT-1a were 16% and 65% lower (Pb0.05), respectively, with a signiﬁcant 62%
enhancement in the SREBP-1c/PPAR-α ratio. Liver n-3 LCPUFA levels were 53% lower in obese patients who
also showed IR and hipoadiponectinemia over controls (Pb0.05). IR negatively correlated with both the
hepatic content of n-3 LCPUFA (r=−0.55; Pb0.01) and the plasma levels of adiponectin (r=−0.62;
Pb0.005). Liver SREBP-1c/PPAR-α ratio and n-3 LCPUFA showed a negative correlation (r=−0.48; Pb0.02)
and positive associations with either HOMA (r=0.75; Pb0.0001) or serum insulin levels (r=0.69;
Pb0.001). In conclusion, liver up-regulation of SREBP-1c and down-regulation of PPAR-α occur in obese
patients, with enhancement in the SREBP-1c/PPAR-α ratio associated with n-3 LCPUFA depletion and IR, a
condition that may favor lipogenesis over FA oxidation thereby leading to steatosis.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Non-alcoholic fatty liver disease (NAFLD) represents the hepatic
metabolic consequence of relative overnutrition and altered diet
composition in the setting of reduced physical activity and sedentary
behaviors [1,2]. Under these conditions, carbohydrate and lipid
afﬂuence determine signiﬁcant changes in hepatic intermediary
metabolism, with high blood glucose and insulin levels stimulating
liver fatty acid (FA) synthesis from glucose, re-directing FAs towardsolecular y Clínica, Instituto de
de Chile, Independencia 1027,
56 2 7372783.
ll rights reserved.triacylglycerol (TAG) formation [3]. These changes seem to play a key
role in the onset of hepatic steatosis by overnutrition, which may be
contributed by the development of insulin resistance (IR) promoting
peripheral FA mobilization to the liver [4,5]. Although IR determines a
derangement in the gluco-regulatory action of insulin, the lipogenic
effects of insulin in the liver are preserved [1–3], in agreement with
the higher hepatic contents of palmitic acid and TAGs observed in
obese patients over control values [6].
An additional major metabolic disturbance observed in the liver
of obese NAFLD patients is n-3 long-chain polyunsaturated FA (n-3
LCPUFA) depletion, as evidenced by the substantial diminution in
eicosapentaenoic acid (20:5, n-3; EPA) and docosahexaenoic acid
(22:6, n-3; DHA) levels [6,7]. This ﬁnding has been related to higher
utilization of n-3 LCPUFA due to oxidative stress [8] and defective
Table 1
Clinical and biochemical parameters in control subjects and in obese patients with
NAFLD.




Age (year) 40±6 33±2
Female/male ratio 6/2 7/4
Body weight (kg) 65±2 .6 110±5.1a
Body mass index (b25 kg/m2) 25.0±0.6 41.5±2.1a
Waist circumference (cm) 89.7±6.6 113±4.2a
Glucose (b100 mg/dL) 89.8±3.4 93.5±3.6
Insulin (b20 μU/mL) 6.6±0.71 25.6±3.7a
HOMA (b2.5) 1.3±0.2 6.0±0.9a
Adiponectin (μg/mL) 14.0±1.4 9.34±1.00a
Liver parameters
Alanine aminotransferase (9–52 IU/L) 39±3.8 60±10
Aspartate aminotransferase (14–36 IU/L) 25±2.1 43±5a
Alkaline phosphatase (38–126 IU/L) 96±11 85±8
γ-Glutamyl transpeptidase (12–43 IU/L) 42±6 41±7
Total bilirubin (0.2–1.3 mg/dL) 0.46±0.08 0.48±0.08
Lipid proﬁle
Total triglyceride (b150 mg/dL) 163±63 170±31
Total cholesterol (b200 mg/dL) 163±15 190±16
LDL-cholesterol (b140 mg/dL) 87±11 109±12
HDL-cholesterol (N40 mg/dL) 53±7 40±3
Iron metabolism
Total iron (37–145 μg/dL) 64±12 69±9
Ferritin (ng/mL) 54±23 136±51
Transferrin (200–300 mg/dL) 259±21 263±13
Transferrin saturation (20–55%) 22±4 23±3
Values represent means±S.E.M., for the number of subjects indicated.
a Pb0.05 compared with controls, as assessed by Student's t-test for unpaired data.
Abbreviations: HOMA, homeostasis model assessment of insulin resistance [fasting
insulin (μunits/mL)× fasting glucose (mmol/L)/22.5] [15]; LDL, low-density
lipoprotein; HDL, high-density lipoprotein.
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[6,9], which may be compounded by dietary imbalance [6]. Under
physiological conditions, the n-3 LCPUFAs EPA and DHA and/or
their oxidized derivatives constitute signaling molecules regulating
hepatic lipid metabolism. This is achieved through (i) up-regulation
of the expression of genes encoding proteins involved in lipid
transport, FA oxidation, and thermogenesis, acting a ligand of
peroxisome proliferator-activated receptor α (PPAR-α); and (ii)
suppression of lipogenesis by down-regulation of sterol regulatory
element binding protein 1c (SREBP-1c) [10–12]. Therefore, depletion
of n-3 LCPUFA in the liver of obese NAFLD patients might favor FA and
TAG formation over FA oxidation, promoting hepatic steatosis [3],
which may be compromised by derangement in TAG export from the
liver [13]. In view of these considerations, changes in the expression of
SREBP-1c and PPAR-α were assessed in liver samples from control
subjects and obese patients with NAFLD, as potential molecular
mechanisms of hepatic steatosis, in association with that of the
respective target genes fatty acid synthase (FAS) and carnitine
palmitoyltransferase-1a (CPT-1a). Correlations between liver SREBP-
1c, PPAR-α, and the respective SREBP-1c/PPAR-α ratio with the
homeostasis model assessment of IR (HOMA) and the content of
hepatic n-3 LCPUFA were established, in addition to those with the
serum levels of adiponectin, a key signaling adipokine inﬂuencing IR
and glucose and lipid metabolism in the liver [14].
2. Materials and methods
2.1. Patients and laboratory studies
Nineteen subjects attending the Department of Medicine of the
University of Chile Clinical Hospital were studied, including eleven
NAFLD patients [average body mass index (BMI) of 41.5±2.1 kg/m2,
age of 33±2 years], who underwent subtotal gastrectomy with a
gastro-jejunal anastomosis in roux and Y as a therapy for obesity, and
eight non-obese patients [BMI of 25.0±0.6 kg/m2, age of 40±6 years]
who underwent laparoscopic cholecystectomy (control group). The
protocol was explained in detail to the subjects, who then gave
their written informed consent to participate in the study before
any procedure was undertaken. Exclusion criteria included positive
hepatitis B or C serology, positive antibodies (antinuclear, anti-
mitochondrial, and anti-smooth muscle antibodies), smoking habits
or non-smokers b1-year cessation, and consumption of more than
40 g of ethanol per week. Nutritional and alcohol consumption
histories with anthropometric measurements were obtained. Insulin
resistance was calculated from the fasting insulin and glucose
values by homeostasis model assessment (HOMA) of insulin
resistance analysis (fasting insulin (μunits/mL)×fasting glucose
(mmol/l)/22.5) [15]. Plasma adiponectin concentrations were
measured in duplicate by radioimmunoassay with antibody against
human adiponectin and dilution of recombinant adiponectin as
standard, with inter- and intra-assay coefﬁcients of variations of
b7% and b5%, respectively (Linco Research, St. Charles, MO, USA).
Laboratory tests included serum liver parameters, lipid proﬁle, and
iron metabolism parameters (Table 1).
Both control and obese NAFLD patients were subjected to a diet of
25 kcal/kg body weight (where 1 kcal=4.184 kJ), with 30% of the
energy given as lipids and 15% as proteins, for at least 2 days prior to
surgery, and liver tissue of approximately 2 cm3 for histological
diagnoses, n-3 LCPUFA composition, and SREBP-1c and PPAR-αmRNA
determinations were taken during surgery. The samples were ﬁxed in
10% formalin, parafﬁn embedded, and sections were stained with
hematoxylin/eosin and Van Gieson,s stains. Sections of each liver
sample were observed in a blinded manner and evaluated for
histological alterations by means of previously deﬁned codes [6–8].
Liver samples for biochemical determinations were frozen at−80 °C.
The Ethics Committee of the University of Chile Clinical Hospital andthat of the Faculty of Medicine, University of Chile approved the study
protocol that was performed in accordance with the Helsinki
Declaration II criteria.
2.2. Isolation of hepatic RNA and reverse transcription-polymerase chain
reaction (RT-PCR) assay for SREBP-1c and PPAR-α mRNA
Total liver RNA was extracted with Trizol reagent (Invitrogen
Corp., Carlsbad, CA, USA) [16] and quantiﬁed by measurement of
ultraviolet absorption at 260 nm. For RT-PCR assay of mRNA, ﬁrst-
strand cDNA was synthesized from total RNA (5 μg) using Thermo-
Script RT-PCR System (Invitrogen Corp., Carlsbad, CA, USA). cDNA
was ampliﬁed in a PCR reaction using Taq DNA polymerase
(Invitrogen Corp., Carlsbad, CA, USA) in the presence of primers
speciﬁc for human SREBP-1c and PPAR-α. Nucleotide sequences for
sense and antisense primers used were 5,-GGATTGCACTTTCGAAGA-
CATG-3, and 5,-ACTCTGGACCTGGGTGTGCAAG-3, for SREBP-1c and
5,-AGCCCGTTATCTGAAGAGTTCC-3, and 5,-CATCCCGACAGAAAGG-
CACTTG-3, for PPAR-α (Invitrogen Corp., Carlsbad, CA, USA),
respectively. In these conditions, a 547-bp sequence between +3
and +549 bp of human SREBP-1c and a 438 bp sequence between
+61 and +498 bp of human PPAR-α were ampliﬁed. To control the
relative amount of total mRNA transcribed in each reverse trans-
criptase reaction, an RNA 18S invariant standard [Classic II 18S
Internal Standards (324 bp); Ambion, The RNA Co., Austin, TX, USA]
was used. PCR conditions included denaturation, annealing, and
extension at 94, 64, and 72 °C, for 30 s, 75 s, and 60 s, respectively, for
38 and 39 cycles. PCR products were electrophoresed on 1.2% agarose
gels containing ethidium bromide, visualized by UV-induced ﬂuor-
escence, and analyzed by densitometry using Scion Image (Scion
Corp., Frederick, MD, USA).
Table 2
Content of EPA and DHA in liver total lipids from control subjects and obese patients
with NAFLD.
Fatty acid Controls (n=8) Obese NAFLD patients (n=11)
EPA (g/100 g FAME) 1.30±0.37 1.36±0.42
DHA (g/100 g FAME) 18.5±1.7 7.90±1.30a
EPA+DHA (g/100 g FAME) 19.8±1.8 9.30±1.60a
Values represent means±S.E.M., for the number of subjects indicated.
a Pb0.05 compared with controls, as assessed by Student's t-test for unpaired data.
Abbreviations: DHA, docosahexaenoic acid (22:6, n-3); EPA, eicosapentaenoic acid
(20:5, n-3); FAME, fatty acid methyl esters.
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Total RNA was extracted from homogenized liver biopsies with
Trizol reagent (Invitrogen Corp., Carlsbad, CA, USA). Quality and
quantity of RNA was checked visually prior to and after DNAase
digestion (TURBO DNAase-free, Ambion, The RNA Co., Austin, TX,
USA) by denaturing gel electrophoresis and by photometric
analysis (A260 and A280). Synthesis of cDNA was performed with
2 μg of total RNA using SyperScrip III (Invitrogen Corp., Carlsbad,
CA, USA) and random hexamers according to standard procedures.
Real-time RT-PCR reactions were performed in a LightCycler
system (Roche Diagnostics, Mannheim, Germany) using SYBR
Green to monitor cDNA ampliﬁcation. Equal amounts of cDNA
corresponding to 1/15 dilution of cDNA were used in each
reaction, containing 5 μL Platinum SYBR Green I SuperMix-UDG,
0.5 μL BSA 20×(Invitrogen Corp., Carlsbad, CA, USA), and 5 pmol
of forward and reverse primers in a total volume of 10 μL. The
standard thermal proﬁle used was 2 min at 50 °C, 2 min at 95 °C,
50 repeats of 5 s at 95 °C, 15 s at 60 °C, and a ﬁnal stage of 15 s at
72 °C. Data were analyzed using LightCycler3 analysis software
(Roche Diagnostics, Mannheim, Germany). PCR efﬁciency was
determined for each sample and gene by LinRegPCR v7.5 [17].
Two technical repeats were done for each combination of cDNA
and primer pair, and the quality of the PCR reactions was checked
through analysis of the dissociation and ampliﬁcation curves. The
products were resolved by 3% agarose gel electrophoresis to
conﬁrm the DNA fragments of expected size. Transcript levels of
genes were normalized to the respective transcript level of
constitutively expressed control gene, human large ribosomal
protein Rp1p0 [18]. Values shown are relative transcript level
(RTL)×1000. The PCR primers for ampliﬁcation of FAS (NM
004104.4) were forward 5,-GGACTACAACCTCTCCCA-3, and reverse
5,-GGATGATGCTGATGATGGA-3, and of CPT-1a (NM 001876.3)
were forward 5,-CGCTACTCCCTGAAAGTG-3, and reverse 5,-CTT-
GACCATACCCATCCAG-3, (Invitrogen Corp., Carlsbad, CA, USA).
2.4. Determination of liver n-3 LCPUFA
Liver samples frozen in liquid nitrogen were homogenized
(50 mg/mL) in a buffer solution pH 7.9 containing 10 mM HEPES,
1 mM EDTA, 0.6% Nonidet P-40, 150 mM NaCl, and protease inhi-
bitors (1 mM phenylmethylsulfonyl ﬂuoride, 1 μg/mL aprotinin,
1 μg/mL leupeptin, and 1 mM orthovanadate). To determine the
changes in the levels of EPA (20:5,n-3) and DHA (22:6, n-3), lipids
were extracted and derivatized to FA methyl esters (FAME) [19].
Brieﬂy, liver homogenates containing the internal standard were
extracted with a methanol/chloroform/H2O mixture (2/1/1.8 by
vol) and FAME in all samples was analyzed by GLC, as described
previously [6]. The individual FAME peaks were identiﬁed by
comparison of the retention times of the individual FAs from an
authentic standard mixture and converted to concentration using
the 17:0 internal standard. Results are expressed as g of n-3
LCPUFA/100 g FAME.
2.5. Statistical analyses
Data showing Gaussian distribution using the Kolmogorov–
Smirnov test are expressed as means±S.E.M. for the number of
patients indicated. Statistical analysis of the differences between
mean values from control subjects and obese NAFLD patients was
assessed by Student's t-test for unpaired data. The differences were
considered statistically signiﬁcant at Pb0.05. To analyze the
association between different variables, the Spearman rank order
correlation coefﬁcient was used. All statistical analyses were
computed using GraphPad Prism™ version 2.0 (GraphPad Software
Inc., San Diego, CA, USA).3. Results
3.1. Clinical and biochemical characteristics of obese patients and
control subjects
Table 1 shows the general characteristics of the patients studied.
Subjects were predominantly female and exhibited comparable ages.
Control patients (n=8) had normal liver histology, whereas those in
the obese group (n=11) presented either simple macrovesicular
steatosis (n=7) or steatosis and lobular inﬂammation with hepato-
cyte ballooning (steatohepatitis)(n=4). NAFLD patients were sig-
niﬁcantly more obese than controls, as evidenced by their body
weight, body mass index, and waist circumference being 69%, 66%,
and 26% higher than controls, respectively. Fasting blood glucose
levels in control and NAFLD patients were comparable, whereas
fasting insulin levels in obese patients were 284% higher than
controls (Pb0.05), resulting in 359% enhancement (Pb0.05) in the
HOMA index of IR. Fasting levels of plasma adiponectin in obese
patients were 33% lower (Pb0.05) than control values. The majority
of patients were asymptomatic, with plasma lipid levels (total
cholesterol, HDL-cholesterol, LDL-cholesterol, and triacylglycerols),
parameters related to iron metabolism (total iron, ferritin, transfer-
rin, and transferrin saturation), and alkaline phosphatase and γ-
glutamyl transpeptidase activity in serum and total serum bilirubin
being within normal ranges in the studied groups. Control patients
exhibited normal serum ALT and AST activity, whereas six (55%)
obese NAFLD patients exhibited serum ALT and AST levels higher
than the normal range. Considering that liver TAG content and the
changes in the hepatic composition of n-6 and n-3 PUFA are
comparable in obese NAFLD patients with steatosis or steatohepatitis
[6,7], all obese patients studied were joined in a single group.
3.2. Obesity is associated with liver n-3 LCPUFA depletion
The content of EPA in the liver of obese NAFLD patients was
comparable to that in control subjects (Table 2). However, the content
of DHA was 57% lower (Pb0.05) in the liver of obese patients than
control values, with a net 53% diminution being observed in the total
n-3 LCPUFA (EPA+DHA) content (Table 2).
3.3. Obesity is related to liver SREBP-1c and FAS up-regulation and
PPAR-α and CPT-1a down-regulation
The upper panels of Fig. 1A and B show representative agarose gel
electrophoresis of the RT-PCR products for SREBP-1c mRNA and
PPAR-αmRNA, respectively, with those of 18S rRNA to compare lane-
lane equivalency in total RNA content in liver samples from control
patient 1, NAFLD patient 2 with steatosis, and NAFLD patient 3 with
steatohepatitis. Densitometric quantiﬁcation of RT-PCR products of
the mRNA of SREBP-1c in the liver of obese NAFLD patients,
expressed as SREBP-1c mRNA/18S rRNA, revealed values 33% higher
than those in the control group (Pb0.05) (Fig. 1A, lower panel),
whereas hepatic PPAR-α mRNA/18S rRNA were 16% lower (Pb0.05)
in obese patients over controls (Fig. 1B, lower panel). Accordingly,
Fig. 1. Expression of SREBP-1c mRNA (A), PPAR-αmRNA (B), and SREBP-1c mRNA/PPAR-αmRNA ratio (C) in the liver of control subjects and obese patients with NAFLD. The upper
panels represent agarose gel electrophoresis of the RT-PCR products for SREBP-1c mRNA (547 bp) and 18S rRNA (324 bp)(A) and for PPAR-αmRNA (438 bp) and 18S rRNA (324 bp)
(B) in total liver RNA samples (5 μg) from patient 1 (control), patient 2 (steatosis), and patients 3 (steatohepatitis). Bar graphs in the lower panels corresponding to densitometric
quantiﬁcation of relative SREBP-1c mRNA (SREBP-1c mRNA/18S rRNA)(A) and PPAR-α mRNA (PPAR-α mRNA/18S rRNA)(B) levels represent means±S.E.M. for the number of
patients indicated in parentheses. aPb0.05 compared to controls, as assessed by Student's t-test for unpaired data.
Fig. 2. Expression of fatty acid synthase (FAS) mRNA and carnitine palmitoyltransfer-
ase-1a (CPT-1a) mRNA in the liver of controls subjects (n=8) and obese patients
(n=11) with NAFLD. Measurements were carried out by real-time RT-PCR and values
shown were normalized to the respective transcript level of the constitutively
expressed control gene Rp1p0, expressed as means±S.E.M. for the number of patients
indicated in parentheses. aPb0.05 compared to controls, as assessed by Student's t-test
for unpaired data.
1083P. Pettinelli et al. / Biochimica et Biophysica Acta 1792 (2009) 1080–1086the liver of obese patients exhibited respective calculated SREBP-1c
mRNA/PPAR-α mRNA ratios 62% higher (Pb0.05) than control
subjects (Fig. 1C). Values for the SREBP-1c mRNA/PPAR-α mRNA
ratios were comparable in obese patients with esteatosis and steato-
hepatitis (data not shown). Up-regulation of SREBP-1c in the liver of
obese patients (Fig. 1A) coincided with a 70% enhancement in the
mRNA expression of hepatic FAS over controls (Fig. 2), parameters
that were signiﬁcantly correlated in the studied patients (r=0.88;
Pb0.0001). Furthermore, down-regulation of hepatic PPAR-α
(Fig. 1B) was associated with a signiﬁcant 65% diminution in the
levels of liver CPT-1a mRNA (Fig. 2) (r=0.86; Pb0.0001).
3.4. Liver SREBP-1c/PPAR-α ratios are positively correlated with serum
insulin levels or with HOMA and negatively associated with liver n-3
LCPUFA levels
In the studied patients, IR assessed by the HOMA index negatively
correlated with both the hepatic content of n-3-LCPUFA (r=−0.55;
Pb0.01) and the plasma levels of adiponectin (r=−0.62; Pb0.005).
Liver SREBP-1c mRNA expression showed a positive correlation
with HOMA (r=0.43; Pb0.05), without signiﬁcant association with
the plasma levels of adiponectin (r=−0.09; not signiﬁcant).
Hepatic PPAR-α mRNA expression negatively correlated with
HOMA (r=−0.44; Pb0.05) and showed a positive associationwith the plasma adiponectin levels (r=0.54; Pb0.01). Furthermore,
the SREBP-1c/PPAR-α mRNA ratio and n-3 LCPUFA showed a
negative signiﬁcant correlation (r=−0.48; Pb0.02) (Fig. 3A) and
signiﬁcant positive associations with either HOMA (r=0.75;
Fig. 3. Correlations between liver SREBP-1c/PPAR-α mRNA ratio and the hepatic
content of n-3 LCPUFA content (A), the homeostasis model assessment of insulin
resistance (HOMA)(B), and the plasma levels of adiponectin (C) in control subjects and
obese NAFLD patients. The Spearman rank order correlation coefﬁcient was used to
analyze the association between different variables.
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whereas that with plasma adiponectin levels was not signiﬁcant
(r=−0.36; PN0.05) (Fig. 3C).
4. Discussion
Saturated FAs are the major metabolic fuel in the liver under most
circumstances in healthy human subjects, whereas the contribution
of hepatic de novo lipogenesis (DNL) to TAG content is very small
(1.6–4.7%) [20,21]. However, in insulin-resistant states such that
occurring in obese hyperinsulinemic NAFLD patients, fasting DNL is
substantially increased, a response that is likely to involve up-
regulation of the enzymes of hepatic DNL [20,21]. Data presented in
this study show that the liver of obese NAFLD patients exhibit levels
of the pro-lipogenic transcription factor SREBP-1c that are 33% higher
than lean controls. Up-regulation of liver SREBP-1c is in agreementwith the enhanced DNL observed in obesity [20–22], considering that
SREBP-1c transcriptionally activates most genes required for hepatic
lipogenesis [23], as shown by the 70% increase in FAS expression.
Insulin is known to activate the hepatic expression of SREBP-1c
under normal conditions [23], an action that persists in IR states
underlying hyperinsulinemia such as that observed in the current
study (Fig. 4). This contention is supported by the signiﬁcant corre-
lation found between liver SREBP-1c mRNA levels and HOMA
established. In addition to this mechanism, increased liver DNL in
obese NAFLD patients may be contributed by the hepatic n-3 LCPUFA
depletion observed, favoring the proteolytic release of membrane-
bound SREBP-1c and its nuclear abundance and/or altering mem-
brane lipid composition associated with IR (Fig. 4) [10–12]. In addi-
tion to the above mechanisms triggering SREBP-1c transcription and
processing, interference with SREBP-1c ubiquitination and/or
sumoylation by speciﬁc enzymes may also play a role in enhancing
SREBP-1c transcriptional activity [24]. However, this contention
underlying diminished degradation and/or inactivation of SREBP-
1c, respectively, remains to be studied in the liver of obese patients.
Up-regulation of liver SREBP-1c in obesity was found concomi-
tantly with down-regulation of hepatic PPAR-α, as evidenced by the
signiﬁcant diminution in PPAR-αmRNA levels over control values, in
association with a 65% decrease in PPAR-α-dependent CPT-1a
expression. Data reported in human liver indicate that PPAR-α
expression (i) is lower than in rodent liver [25]; (ii) represents a
functional and conserved process capable of trans-activating response
elements in genes responsible for FA oxidation and lipid transport
[26,27]; and (iii) is regulated by genetic and/or environmental factors
[28]. According to the latter view, obesity-associated liver down-
regulation of PPAR-α expression in NAFLD patients may be related to
the expression of a PPAR-α variant transcript [25,28], leading to
production of a truncated form of PPAR-α that upon nuclear trans-
location exerts a potent dominant negative activity [28]. Furthermore,
down-regulation of liver PPAR-α mRNA expression in obese NAFLD
subjects could be achieved through a tumor necrosis factor-α
(TNF-α)-dependent mechanism as shown for PPAR-γ [29], con-
sidering the pro-inﬂammatory cytokine signaling established in
NAFLD [1–3,30]. However, further studies in obese NAFLD patients
are needed to support the involvement of both PPAR-α splice
variant and TNF-α in liver PPAR-α mRNA down-regulation. In
addition to obesity-induced changes in liver PPAR-α transcription,
transcriptional activation of PPAR-α target genes should also be
considered, as this complex phenomenon requires the binding of
speciﬁc ligands and the orchestrated recruitment and assembly of
several cofactors into multi-subunit protein co-activator complexes
on promoters [27]. Considering that human PPAR-α is activated
through direct binding of LCPUFA to its ligand-binding domain
[31], liver PPAR-α function may be compromised in obesity by
deﬁcient PPAR-α activation due to diminished binding of n-3
LCPUFA secondary to depletion of these naturally occurring ligands
(Fig. 4) reported in this work (Table 2) and elsewhere [6,7,32].
Alternatively, availability of co-activators of PPAR-α function may
be reduced, as shown for CREB-binding protein (CBP) in subjects
expressing truncated PPAR-α [28]. Finally, in the studied patients,
liver PPAR-α expression positively correlated with plasma adipo-
nectin levels, whereas it showed a negative association with
HOMA. These correlations suggest that hypoadiponectinemia in
IR-obese NAFLD patients may impair liver PPAR-α function, as
hypothesized from data obtained in experimental obese animals
[33]. However, this aspect and availability of PPAR-α co-activators
in PPAR-α function require further investigation in human obesity.
Down-regulation of liver PPAR-α expression without signiﬁcant
alteration in that of SREBP-1 has been reported in NAFLD [34],
changes that are difﬁcult to interpret due to lack of assessment of
clinical and biochemical parameters including body mass index, IR,
and liver function tests. Recently, NAFLD patients with BMI≥25
Fig. 4. Dysregulation of liver lipid metabolism leading to hepatic steatosis in obese NAFLD patients. FA loading underlying overnutrition can increase mitochondrial production of
reactive oxygen species (ROS) leading to (i) depletion of n-3 LCPUFA due to enhanced lipid peroxidation, with the involvement of dietary imbalance and decreased FA desaturation;
and (ii) the onset of IR due to ROS- and FA-dependent activation of serine-threonine kinases that phosphorylate the insulin receptor and related insulin-receptor substrates thus
decreasing insulin signaling [3,36]. Hyperinsulinemia secondary to IR and liver n-3 LCPUFA depletion up-regulate the expression and processing of hepatic SREBP-1c, respectively,
which occur concomitantly with liver PPAR-α deactivation coupled to n-3 LCPUFA depletion. The substantial increase in the SREBP-1c/PPAR-αmRNA content ratio is associated with
an enhanced lipogenic potential relative to FA oxidation and export, a change that is favored by increased FA ﬂux into the plasma nonesteriﬁed FA (NEFA) pool due to IR-dependent
peripheral lipolysis thus determining liver steatosis.
1085P. Pettinelli et al. / Biochimica et Biophysica Acta 1792 (2009) 1080–1086exhibited signiﬁcantly lower liver PPAR-α mRNA levels over those
with BMIb25, in agreement with our results, however, liver SREBP-
1c expression was comparable in the studied groups [35]. The
discrepancy observed in liver SREBP-1c expression could be due to
the fact that obese patients in our study exhibited morbid obesity,
as evidenced by BMIN40 (Table 1).
A major ﬁnding in the current study is the substantial enhance-
ment in the hepatic SREBP-1c/PPAR-α mRNA content ratio found in
obesity, implying a metabolic imbalance between DNL and FA
oxidation in favor of the former as a central issue determining liver
steatosis in NAFLD (Fig. 4). Furthermore, liver SREBP-1c/PPAR-α ratio
is signiﬁcantly correlated with both HOMA and serum insulin levels,
pro-lipogenic factors conditioning the increases in peripheral lipolysis
and in the nonesteriﬁed FA plasma pool reaching the liver (Fig. 4). Of
particular interest is the negative (Pb0.02) correlation established
between liver SREBP-1c/PPAR-α ratio and n-3 LCPUFA content in
control and obese NAFLD patients, which support the crucial role of
the depletion of n-3 LCPUFA as a fuel partitioning factor directing FAs
away from oxidation and toward TAG storage [36]. In agreement with
this view, obese NAFLD patients supplemented with n-3 LCPUFA for
12 months ameliorated hepatic steatosis compared with similar
patients refusing the treatment, as measured by ultrasonography and
echo-Doppler, although cellular n-3 LCPUFA status and IR were not
assessed [37]. Thus, considering that steatosis in the obese NAFLD
patient is the result of multiple metabolic abnormalities taking place
in the setting of dietary imbalance and involving the onset of
oxidative stress and IR (Fig. 4), future therapeutic trials may require
different treatment targets [38].
In conclusion, the expression of transcription factors controlling
lipid metabolism is markedly altered in the liver of obese NAFLD
patients. This is evidenced by the increased mRNA expression of
SREBP-1c inducing lipogenic genes such as FAS, with the parallel
diminution in that of PPAR-α controlling FA oxidation (CPT-1a) and
secretion. Consequently, the liver SREBP-1c/PPAR-α ratio is substan-
tially elevated, a change that may determine higher rates of hepatic
lipogenesis over those of FA oxidation, with development of steatosis.
Although hepatic DNL is mainly controlled by SREBP-1c signaling
ampliﬁed by nuclear factor Y and stimulatory protein 1 [12,24,36],
induction of SREBP-1c by liver X receptor-α and/or activation of
carbohydrate response element binding protein could also play a role[12,39], however, further studies are required to verify this contention
in human morbid obesity. Down-regulation of hepatic PPAR-α in
NAFLD reported in this work may have a pro-inﬂammatory connota-
tion, considering the antagonizing effect of PPAR-α on nuclear factor-
κB and activating protein-1 action [2], in agreement with the
enhancement in the activity of the latter pro-inﬂammatory mediators
recently reported in the liver of obese NAFLD patients with
steatohepatitis [40].
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